Calendar Chengdu Olymvax Biopharmaceuticals Inc.

Equities

688319

CNE1000051H8

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
9.1 CNY +1.79% Intraday chart for Chengdu Olymvax Biopharmaceuticals Inc. +3.29% -42.41%

Chart calendar Chengdu Olymvax Biopharmaceuticals Inc.

086454523c.6cWddosm5GWkXJCgpqGyxHjQEvzndoNhqkipRvd6Cc8.vYvyR7JFoAHHONnU4_bK9A22cLbTRs4CmQ3qLoYJSpCDqvoV2l-cXJJlpA~69a21d9b640c8641841848bc838673f4

Upcoming events on Chengdu Olymvax Biopharmaceuticals Inc.

2024-08-15 Q2 2024 Earnings Release (Projected)
2024-10-27 Q3 2024 Earnings Release (Projected)
2025-04-23 Q1 2025 Earnings Release (Projected)
2025-04-23 Q4 2024 Earnings Release (Projected)

Past events on Chengdu Olymvax Biopharmaceuticals Inc.

2024-04-25 Q4 2023 Earnings Release
2024-04-24 Q1 2024 Earnings Release
2023-10-26 Q3 2023 Earnings Release
2023-08-17 Q2 2023 Earnings Release
2023-04-25 Q4 2022 Earnings Release
2023-04-25 Q1 2023 Earnings Release
2022-10-28 Q3 2022 Earnings Release
2022-08-17 Interim 2022 Earnings Release
2022-04-27 Q1 2022 Earnings Release
2022-04-27 FY 2021 Earnings Release

Annual results

Fiscal PeriodDecember 2020 2021 2022 2023 2024
Net sales
Million CNY
Released
Forecast
Spread
320


487
513
-5.04%
547
595
-7.99%
496
633
-21.59%

658

EBITDA
Million CNY
Released
Forecast
Spread
0,00


126
132
-4.35%
70,3
87,0
-19.15%
33,4
105
-68.22%

120

EBIT
Million CNY
Released
Forecast
Spread
0,00


102
124
-18.08%
41,6
64,0
-34.97%
3,40
69,6
-95.11%

126

Earnings before Tax (EBT)
Million CNY
Released
Forecast
Spread
0,00


107
124
-13.56%
43,6
64,0
-31.8%
15,9
71,9
-77.87%

127

Net income
Million CNY
Released
Forecast
Spread
36,9


108
124
-12.93%
26,6
64,0
-58.47%
17,4
61,3
-71.58%

79,0

EPS
CNY
Released
Forecast
Spread
0,00


0,28
0,31
-9.55%
0,07
0,14
-53.14%
0,04
0,15
-70.92%

0,19

Announcement Date18/05/2122/02/2227/02/2327/02/24-

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688319 Stock
  4. Calendar Chengdu Olymvax Biopharmaceuticals Inc.